

16715CIP

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re Application of

William J. Rea, MD, et al

Serial No. 08/902,692

Filed: July 30, 1997

For: **AUTOGENOUS LYMPHATIC FACTOR FOR**

MODIFICATION OF T AND B LYMPHOCYTE PARAMETERS

Attorney Docket: 16715/CIP

Art Unit: 1644

Examiner:

R. Schwadron

Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

TRANSMITTAL OF NEW DECLARATION

In response to the Office Action mailed June 18, 1999, enclosed herewith is a new Declaration for filing in the above-identified application. Please replace this Declaration for the defective Declaration filed February 9, 1998.

DATE: December 20, 1999

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed for Commissioner of Patents and Trademarks, Washington, D. C. 20231

on December 20, 1999

Date of Deposit

Todd E. Albanesi

Name of Applicant, Assignee or Registered Representative

Todd E. Albanesi

Signature

December 20, 1999

Date of Signature

Respectfully submitted,

Todd E. Albanesi

TODD E. ALBANESI, Reg. No. 36,426

CRUTSINGER & BOOTH

Thanksgiving Tower

1601 Elm Street, Suite 1950


Dallas, Texas 75201-4744

Phone: (214) 220-0444

FAX: (214) 220-0445

Attorneys for Applicant

dc/c:\missing\echd3



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: William James Rea, M.D.
and Bertie B. Griffiths, Ph.D.

Attorney Docket No.: 16715CIP

Serial No.: 08/902,692

Art Group Unit: 1644

Filed: July 30, 1997

For: **AUTOGENOUS LYMPHOCYTIC FACTOR FOR MODIFICATION
OF T AND B LYMPHOCYTE PARAMETERS**

DECLARATION FOR UTILITY PATENT APPLICATION

Assistant Commissioner of Patents
Box CPA
Washington, D.C. 20231

RECEIVED

JAN 03 2000

TECH CENTER 1600/2900

Sir:

As the below named inventors, we hereby declare that:

Our residence, post office mailing address, and citizenship are as stated below next to our names.

We believe we are the original, first, and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled **AUTOGENOUS LYMPHOCYTIC FACTOR FOR MODIFICATION OF T AND B LYMPHOCYTE PARAMETERS**, the specification for which is filed herewith.

We hereby state that we have reviewed and understand the contents of the above-identified specification, including the claims.

We acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).


We hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed: None.

We hereby claim the benefit under Title 35, United States Code § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of

Title 35, United States Code, § 112, we acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application: International Patent Application Serial No. PCT/US96/01205, filed January 30, 1996 (designating and electing the United States, now abandoned), which was a continuation of U.S. Application Serial No. 08/380,063 filed January 30, 1995, now abandoned.

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Inventor's signature:




William James Rea, M.D.

Address: 4040 Beaverbrook
Dallas, Texas 75229

Date: 12-13-99

Citizenship: U.S.A.

Inventor's signature:



Bertie B. Griffiths, Ph.D.

Address: 5602 Willowbrook Drive
Rowlett, Texas 75088

Date: 12/13/99

Citizenship: U.S.A.